Article Sidebar

PDF (Tiếng Việt)
Published: 2021-02-26
Abstract Views: 227
Views PDF (Tiếng Việt): 227
DOI: https://doi.org/10.52852/tcncyh.v137i1.43
Issue
Vol. 137 No. 1 (2021)
Section
Các bài báo
How to Cite
Thơ, P. K. A. ., Tùng, L. Đình ., & Bình , N. T. . (2021). Clinical characterization and repetitive nerve stimulation test in patients with myasthenia gravis. Journal of Medical Research, 137(1), 213-221. https://doi.org/10.52852/tcncyh.v137i1.43

Clinical characterization and repetitive nerve stimulation test in patients with myasthenia gravis

Pham Kieu Anh Tho, Le Dinh Tung, Nguyen Thanh Binh

Main Article Content

Abstract

The purpose of this study is to describe the clinical characterization and repetitive nerve stimulation test performed in 30 myasthenic patients by a descriptive research method. The research results noted: the average age was 48.57 years old, the female/male ratio was 2:1; there were 7 patients in group I (23.3%), 7 patients in group IIa (23.3%), 7 patients in group IIb (23.3%), 6 patients in group IIIa (20%), 2 patients in group IIIb (6.7%) and 1 patient in group IVa (3.3%); 73.3% of patients had positive AchRs antibodies, 20% of them have thymoma. Repetitive nerve stimulation test (RNS) was positive in 21 patients (70%), patients with affected ocular muscles only (group I) had a positive RNS test rate of 42.9%, and patients with affected limbs and truncal muscles (groups a: IIa, IIIa, IVa) had a positive RNS test rate of 64.2%, The myasthenic patients with affected respiratory and pharyngeal muscle (groups b: IIb, IIIb) had a 100% positive RNS test rate. In conclusion, there is a statistically significant association between the abnormal result on repetitive nerve stimulation test and the myasthenia gravis classification in clinical settings according to MGFA (p = 0.01) and the AchRs antibody quantitative assay (p = 0.001).

Article Details

Keywords

Myasthenia Gravis, repetitive nerve stimulation test

References

1. Jaretzki AR BR, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical resreach standards, Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55: 16 – 23.
2. Nils Erik Gilhus JJV. Myasthenia gravis: subgroup classifi cation and therapeutic strategies. Lancet Neurol. 2015; 14: 1023 – 1036.
3. Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ. Diagnosis of Myasthenia Gravis. Neurologic Clinics. 2018; 36(2): 261 - 274.
4. Nils Erik Gilhus, Socrates Tzartos. Myasthenia gravis. Disease Primer. 2019; 5: 30.
5. Matthew N Meriggioli DBS. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8: 475 – 490.
6. Howard JF. Electrodiagnosis of Disorders of Neuromuscular Transmission. Physical Medicine and Rehabilitation Clinics of North America. 2013; 24(1): 169 - 192.
7. Preston DC, Shapiro BE. Neuromuscular Junction Disorders. In: Preston DC, Shapiro BE, eds. Electromyography and Neuromuscular Disorders (Third Edition). London: W.B. Saunders; 2013: 529 - 548.
8. Padua L, Caliandro P, Di Iasi G, Pazzaglia C, Ciaraffa F, Evoli A. Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. Clinical Neurophysiology.2014; 125(6): 1270 - 1273.
9. Costa J, Evangelista T, Conceição I, Carvalho Md. Repetitive nerve stimulation in myasthenia gravis—relative sensitivity of different muscles. Clinical Neurophysiology. 2004; 115(12): 2776 - 2782.
10. Committee Aqa. Practice parameter for repetitive nerve stimulation and single fiber emg evaluation of adults with suspected myasthenia gravis or lambert–eaton myasthenic syndrome: Summary statement. Muscle Nerve. 2001; 24: 1236 – 1238.
11. Abraham A, Alabdali M, Alsulaiman A, et al. Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology. 2016; 127(10): 3294 - 3297.
12. Maarika Liik a ARP. Repetitive nerve stimulation often fails to detect abnormal decrement in acute severe generalized Myasthenia Gravis. Clinical Neurophysiology. 2016; 127: 3480 – 3484.
13. Philippe Gajdos MCT, MD. Treatment of Myasthenia Gravis Exacerbation with Intravenous Immunoglobulin. Arch Neurol. 2005; 62: 1689 - 1693.
14. Lingling Fan SM, Yongxiang Yang, Zhongjun Yan, Junchao Li & Zhuyi Li. Clinical differences of early and late-onset myasthenia gravis in 985 patients. Neurological Research. 2018; ISSN: 0161 - 6412: 1743 - 1328.
15.Erik H. Niks m, umesh a. Badrising, md,. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. Muscle Nerve.2003; 28: 236 – 238.
16. Committee Aqa. Literature review of the usefulness of repetitive nerve stimulation and single fiber emg in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or lambert-eaton myasthenic syndrome. Muscle Nerve. 2001; 24: 1239 – 1247.
17. Popperud MIB, Rasmussen, Kerty. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Official Journal of the European Paediatric Neurology Society. 2017; 21; 707–714.